Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.

Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K.

Br J Haematol. 2020 Feb;188(4):e49-e53. doi: 10.1111/bjh.16320. Epub 2019 Dec 18. No abstract available.

2.

Downregulation of HLA Class I Renders Inflammatory Neutrophils More Susceptible to NK Cell-Induced Apoptosis.

Bernson E, Christenson K, Pesce S, Pasanen M, Marcenaro E, Sivori S, Thorén FB.

Front Immunol. 2019 Oct 15;10:2444. doi: 10.3389/fimmu.2019.02444. eCollection 2019.

3.

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.

Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K.

Hum Vaccin Immunother. 2020;16(1):109-111. doi: 10.1080/21645515.2019.1636598. Epub 2019 Jul 24.

4.

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Aurelius J, Möllgård L, Kiffin R, Ewald Sander F, Nilsson S, Thorén FB, Hellstrand K, Martner A.

Leuk Lymphoma. 2019 Nov;60(11):2771-2778. doi: 10.1080/10428194.2019.1599110. Epub 2019 Apr 17.

PMID:
30991860
5.

The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Blood. 2019 Mar 28;133(13):1479-1488. doi: 10.1182/blood-2018-09-874990. Epub 2019 Jan 15.

6.

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.

7.

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Kiffin R, Grauers Wiktorin H, Nilsson MS, Aurelius J, Aydin E, Lenox B, Nilsson JA, Ståhlberg A, Thorén FB, Hellstrand K, Martner A.

Front Oncol. 2018 Jun 18;8:218. doi: 10.3389/fonc.2018.00218. eCollection 2018.

8.

Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.

Wenger A, Werlenius K, Hallner A, Thorén FB, Farahmand D, Tisell M, Smits A, Rydenhag B, Jakola AS, Carén H.

Neoplasia. 2018 Jan;20(1):25-31. doi: 10.1016/j.neo.2017.10.006. Epub 2017 Dec 1.

9.

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Sander FE, Nilsson M, Rydström A, Aurelius J, Riise RE, Movitz C, Bernson E, Kiffin R, Ståhlberg A, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484. doi: 10.1007/s00262-017-2040-9. Epub 2017 Jul 18.

10.

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Leukemia. 2017 Dec;31(12):2552-2559. doi: 10.1038/leu.2017.151. Epub 2017 May 22.

11.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

12.

NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.

Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, Hansson M, Martner A, Thorén FB, Hellstrand K.

J Leukoc Biol. 2017 Aug;102(2):459-466. doi: 10.1189/jlb.5VMA1116-454R. Epub 2017 Mar 14.

PMID:
28292946
13.

Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.

Rydström A, Hallner A, Aurelius J, Sander FE, Bernson E, Kiffin R, Thoren FB, Hellstrand K, Martner A.

J Leukoc Biol. 2017 Aug;102(2):467-474. doi: 10.1189/jlb.5VMA1116-455R. Epub 2017 Feb 24.

PMID:
28235771
14.
15.

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.

Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.

Oncotarget. 2016 May 31;7(22):32046-53. doi: 10.18632/oncotarget.8769.

16.

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.

17.

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.

Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Oncotarget. 2016 Feb 16;7(7):7586-96. doi: 10.18632/oncotarget.7210.

18.

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.

Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncotarget. 2015 Dec 15;6(40):42569-74. doi: 10.18632/oncotarget.5559.

19.

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.

Riise RE, Bernson E, Aurelius J, Martner A, Pesce S, Della Chiesa M, Marcenaro E, Bylund J, Hellstrand K, Moretta L, Moretta A, Thorén FB.

J Immunol. 2015 Aug 1;195(3):1121-8. doi: 10.4049/jimmunol.1500709. Epub 2015 Jun 17.

20.

Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase.

Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, Thorén FB, Ståhlberg A, Hermodsson S, Hellstrand K.

J Immunol. 2015 May 15;194(10):5014-21. doi: 10.4049/jimmunol.1402991. Epub 2015 Apr 13.

Supplemental Content

Loading ...
Support Center